Biohaven Pharmaceutical Holding Company Ltd

NYSE:BHVN  
110.09
-5.91 (-5.10%)
Products, Strategic Combinations

Biohaven Enters Exclusive License And Research Collaboration Agreement With Ku Leuven To Advance First-In-Class TRPM3 Antagonists For The Treatment Of Pain

Published: 01/10/2022 05:15 GMT
Biohaven Pharmaceutical Holding Company Ltd (BHVN) - Biohaven Enters Exclusive License and Research Collaboration Agreement With Ku Leuven to Advance First-in-class Trpm3 Antagonists for the Treatment of Pain.
Biohaven Pharmaceutical Holding - Lead Candidate, Bhv-2100, is Planned to Enter Clinical Development in First Half of 2023 for Treatment of Neuropathic Pain.
Biohaven-acquires Global Rights to Develop, Commercialize First-in-class Transient Receptor Potential Melastatin-3 (trpm3) Channel Antagonists.